Saturday, March 2, 2024

CATEGORY

AbbVie

Simlandi’s Approval Revolutionizes Biosimilar Landscape: A Game-Changer for Humira’s Dominance

Pharmacists in the United States are now granted the authority to substitute a more affordable biosimilar version for AbbVie's high-concentration formulation of Humira without...

AbbVie’s Tepkinly for Lymphoma Patients Approved by NICE

The National Institute for Health and Care Excellence (NICE) has given its approval for the use of AbbVie's CD20xCD3 bispecific antibody, Tepkinly (epcoritamab), within...

AbbVie Launches Parkinson’s Treatment Produodopa in EU Markets

AbbVie has introduced Produodopa (foslevodopa/foscarbidopa) in the European Union, marking a significant advancement in the treatment of advanced Parkinson's disease (PD). This new therapy...

AbbVie’s $8.7 Billion Deal with Cerevel Bolsters Its Neuroscience Portfolio

AbbVie has recently entered a definitive agreement to purchase Cerevel Therapeutics and its expansive neuroscience pipeline for approximately $8.7 billion. The acquisition encompasses various...

AbbVie Acquires ImmunoGen to Diversify Antibody-Drug Conjugates Pipeline

AbbVie has agreed to acquire ImmunoGen, a move that will add the latter's next-generation antibody-drug conjugates (ADCs) to AbbVie's ADC platform and current programs....

NICE-Recommended Parkinson’s Disease Treatment Poised to Benefit Hundreds

The UK's National Institute for Health and Care Excellence (NICE) has recommended levodopa–foscarbidopa (also known as Produodopa and manufactured by AbbVie) as a treatment...

Innovative Subcutaneous Infusion Therapy for Parkinson’s Disease Gains NHS Approval

A groundbreaking therapy for Parkinson's disease, capable of being administered through a 24-hour subcutaneous infusion pump, has received a recommendation for use within the...

Latest news

Sticky Image